ResearcherThe University of MelbourneActive in the last 2 years

Hong He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5335-5433; OpenAlex author ID A5101669337. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 2 papers

Papers 2

PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167236 ↗
Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity. Last author DOI 10.1186/s12964-024-01670-2 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ching‐Seng Ang · 1 shared paper, 2024 · strength 0.23
- Paper Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating a… DOI 10.1186/s12964-024-01670-2 ↗
Yi Ma · 1 shared paper, 2024 · strength 0.23
- Paper Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating a… DOI 10.1186/s12964-024-01670-2 ↗
Mehrdad Nikfarjam · 1 shared paper, 2024 · strength 0.23
- Paper Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating a… DOI 10.1186/s12964-024-01670-2 ↗
Xiao Dong Xu · 1 shared paper, 2024 · strength 0.20
- Paper PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic ca… DOI 10.1016/j.bbadis.2024.167236 ↗
Kai Wang · 1 shared paper, 2024 · strength 0.20
- Paper PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic ca… DOI 10.1016/j.bbadis.2024.167236 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.